Author: admin
Precision BioSciences Announces Dosing of First Patient in Off-The-Shelf CAR T Cell Therapy Phase 1/2a Clinical Trial
First NHL patient treated with allogeneic CAR T in US-based trial DURHAM, North Carolina, April 17, 2019 – Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company...
Precision BioSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
DURHAM, North Carolina, April 1, 2019 – Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome...
Precision BioSciences Announces Pricing of Initial Public Offering
DURHAM, North Carolina, USA, March 28, 2019 – Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS...
Raymond Schinazi Joins Precision BioSciences Board of Directors
DURHAM, North Carolina, USA, March 14, 2019 –Precision BioSciences (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing...
Precision BioSciences Enters Into Private Convertible Note Financing
DURHAM, North Carolina, USA, March 9, 2019 – Precision BioSciences (“Precision” or the “Company”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS...
Precision BioSciences Announces Formation of Scientific Advisory Board With Anderson, Kantarjian, Schinazi and Turtle
DURHAM, North Carolina, USA, January 16, 2019 – Precision BioSciences today announced the formation of its Scientific Advisory Board (SAB) with four key appointments: Kenneth C. Anderson, MD,...
Science Article About the Quest to Cure HBV Brings Context to Precision BioSciences Collaboration With Gilead
Precision BioSciences is pleased to be part of this important feature story from Science Magazine: Forgotten No More – A long-overlooked scourge of millions, hepatitis B is in the crosshairs...
Precision BioSciences Receives the 2018 SEBIO Venture Funding Award
DURHAM, North Carolina, USA, November 15, 2018 – Precision BioSciences announced today that it has been recognized as the recipient of the 2018 Southeast BIO (SEBIO) Venture Funding Award. Abid...
Precision BioSciences and MaxCyte Enter Into Clinical and Commercial License Agreement
Precision BioSciences is pleased to be working with MaxCyte. Read more about our clinical and commercial license agreement to use the MaxCyte electroporation system for non-viral delivery of genome...
Mario G. Pennisi, Australian Life Sciences Industry Leader, Joins Elo-Australia as Resident Director
RESEARCH TRIANGLE PARK, North Carolina, USA and BRISBANE, Australia, October 10, 2018 – Elo Life Systems Inc. announced today that Mario G. Pennisi joined Elo Life Systems as a Resident...
Gilead Sciences and Precision BioSciences Announce Collaboration to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing
FOSTER CITY, Calif. and DURHAM, NC, Sept 12, 2018 – Gilead Sciences (Nasdaq: GILD) and Precision BioSciences announced today that the companies have entered into a strategic collaboration to...
Precision BioSciences Announces Collaboration With University of Pennsylvania to Develop Genome Editing Therapeutics
DURHAM, North Carolina, USA, September 04, 2018 – Precision BioSciences today announced an expansion of their ongoing collaboration with the Gene Therapy Program in the Perelman School of Medicine...
CSO Derek Jantz Discusses Precision's Long History in Genome Editing and the Future of Medicine with PMWC
Precision BioSciences CSO and Co-founder Derek Jantz will present during the Emerging Therapeutics Showcase of the Duke Precision Medicine World Conference (PMWC) on September 25th, 2018 in Durham,...
Penn Announces Publication of Clinically Relevant Genome Editing in Primates Using Precision's ARCUS Platform
Durham, NC July 09, 2018 – The University of Pennsylvania’s Perelman School of Medicine announced today that researchers from Jim Wilson’s Gene Therapy Program have found that using...
Precision BioSciences Raises $110M to Advance ARCUS Genome Editing Programs
DURHAM, North Carolina, USA, June 26 2018 –Precision BioSciences today announced the closing of an oversubscribed $110M Series B financing to further product development efforts based on its...